The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Hepatitis B: Reflections on the current approach to antiviral therapy
Open accessAbstract
This article summarizes the current state of antiviral therapy of hepatitis B with special attention given to areas that remain controversial or poorly defined. Strict adherence to liver association practice guidelines may result in missed opportunities to treat patients with significant underlying liver disease. In particular, recommended ALT thresholds may not appropriately reflect disease activity or degree of fibrosis. There is growing evidence that an alternative treatment paradigm for preventing late-stage disease complications may be indicated in highly viremic patients with early life exposure to hepatitis B. Pegylated interferon therapy is often a better choice for young to middle-aged patients with genotype A and B because of the higher rate of HBeAg seroconversion and a greater chance for HBsAg seroconversion in both HBeAg-positive and -negative patients as compared to nucleoside analogs. Nucleoside analog monotherapy is the current standard of care for many patients. However, long-term monotherapy results in resistance to a variable degree and sequential monotherapy may result in multi-drug resistant virus. Which patients would specifically benefit from early combination therapy also remains poorly defined. The rapidity and robustness of the suppression of HBV DNA while on a nucleoside analog should be monitored relatively early during treatment because it affects treatment outcome and the rate of resistance. While great progress has been made in treating hepatitis B, many important issues require further study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA Level
Chen, C.-J. (2006) · JAMA · doi:10.1001/jama.295.1.65 · Cited by 3,140
Updated definitions of healthy ranges for serum alanine aminotransferase levels
Prati, D., Taioli, E., Zanella, A., Torre, E. D., Butelli, S., Del Vecchio, E., Vianello, L., Zanuso, F., Mozzi, F., Milani, S., et al. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-1-200207020-00006 · Cited by 1,445
Sung, J. J. Y., Wong, M.-L., Bowden, S., Liew, C.-T., Hui, A. Y., Wong, V. W. S., Leung, N. W. Y., Locarnini, S., & Chan, H. L. Y. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.03.009 · Cited by 218
Cited by
Sarin, S. K., Kedarisetty, C. K., Abbas, Z., Amarapurkar, D., Bihari, C., Chan, A. C. Y., Chawla, Y. K., Dokmeci, A. K., Garg, H., Ghazinyan, H., et al. (2014) · Hepatology International · doi:10.1007/s12072-014-9580-2 · Cited by 1,481
EASL Clinical Practice Guidelines: Management of chronic hepatitis B
European Association for the Study of the Liver (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2008.10.001 · Cited by 1,347
Liaw, Y.-F., & Chu, C.-M. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60207-5 · Cited by 1,218
Sarin, S. K., Kumar, A., Almeida, J. A., Chawla, Y. K., Fan, S. T., Garg, H., de Silva, H. J., Hamid, S. S., Jalan, R., Komolmit, P., et al. (2009) · Hepatology International · doi:10.1007/s12072-008-9106-x · Cited by 763
Hepatitis B Virus Resistance to Nucleos(t)ide Analogues
Zoulim, F., & Locarnini, S. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.08.063 · Cited by 706
Self-citation
Metadata
- Authors
- Zoulim, F., & Perrillo, R.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2008
- Volume
- 48
- Pages
- S2-S19
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2094688618
- Cited by
- 167
- References
- 3
- FWCI
- 19.05
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hepatitis B: Reflections on the current approach to antiviral therapy. https://app.cochat.ai/papers/10.1016/j.jhep.2008.01.011
- The paper
- Zoulim, F., & Perrillo, R. (2008). Hepatitis B: Reflections on the current approach to antiviral therapy. Journal of Hepatology. https://doi.org/10.1016/j.jhep.2008.01.011
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.